[HTML][HTML] T cell responses to SARS-CoV-2
A large body of evidence generated in the last two and a half years addresses the roles of T
cells in SARS-CoV-2 infection and following vaccination. Infection or vaccination induces …
cells in SARS-CoV-2 infection and following vaccination. Infection or vaccination induces …
Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis
WY Au, PPH Cheung - Bmj, 2022 - bmj.com
Objective To evaluate the effectiveness of heterologous and homologous covid-19 vaccine
regimens with and without boosting in preventing covid-19 related infection, hospital …
regimens with and without boosting in preventing covid-19 related infection, hospital …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
[HTML][HTML] Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
P Nordström, M Ballin, A Nordström - The Lancet, 2022 - thelancet.com
Background Vaccine effectiveness against COVID-19 beyond 6 months remains
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden
P Nordström, M Ballin, A Nordström - The Lancet Infectious Diseases, 2022 - thelancet.com
Background Real-world evidence supporting vaccination against COVID-19 in individuals
who have recovered from a previous SARS-CoV-2 infection is sparse. We aimed to …
who have recovered from a previous SARS-CoV-2 infection is sparse. We aimed to …
[HTML][HTML] Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in …
ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley… - The Lancet, 2022 - thelancet.com
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
[HTML][HTML] The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis
K Rahmani, R Shavaleh, M Forouhi… - Frontiers in public …, 2022 - frontiersin.org
Background Vaccination, one of the most important and effective ways of preventing
infectious diseases, has recently been used to control the COVID-19 pandemic. The present …
infectious diseases, has recently been used to control the COVID-19 pandemic. The present …
Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome
Conclusions SARS‐CoV‐2 vaccination can be associated with liver injury. Corticosteroid
therapy may be beneficial in those with immune‐mediated features or severe hepatitis …
therapy may be beneficial in those with immune‐mediated features or severe hepatitis …
[HTML][HTML] Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent …
R Groß, M Zanoni, A Seidel, C Conzelmann, A Gilg… - …, 2022 - thelancet.com
Background Heterologous COVID-19 vaccination regimens combining vector-and mRNA-
based vaccines are already administered, but data on solicited adverse reactions …
based vaccines are already administered, but data on solicited adverse reactions …
[HTML][HTML] A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
CY Wang, KP Hwang, HK Kuo… - The Journal of …, 2022 - Am Soc Clin Investig
Background The Delta and Omicron variants of SARS-CoV-2 are currently responsible for
breakthrough infections due to waning immunity. We report phase I/II trial results of UB-612 …
breakthrough infections due to waning immunity. We report phase I/II trial results of UB-612 …